Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00355342|
Recruitment Status : Completed
First Posted : July 21, 2006
Last Update Posted : October 28, 2016
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Disease, Chronic Obstructive||Drug: fluticasone propionate/salmeterol powder Drug: salmeterol powder||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||180 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|
|Study Start Date :||April 2004|
|Primary Completion Date :||September 2007|
|Study Completion Date :||September 2007|
|Experimental: Arm 1||
Drug: fluticasone propionate/salmeterol powder
Drug: salmeterol powder
Other Name: fluticasone propionate/salmeterol powder
- Bone mineral density measured at the lumbar spine.
- Bone mineral density measured at the total hip.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00355342
Show 37 Study Locations
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|